View in EDS

Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer.

Saved in:
Bibliographic Details
Title: Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer.
Authors: Raimondi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Tinè G; Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Boige V; Department of Oncologic Medicine, Gustave-Roussy, Villejuif Cedex, France., Ballhausen A; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany., Gourgou S; Biometrics Unit, Cancer Institute of Montpellier, Montpellier, France., Stahler A; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany., Randon G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Manca P; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Brument E; UCGI, Prodige Intergroup, UNICANCER, Paris, France., Alig AHS; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany., Morano F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Prisciandaro M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Ambrosini M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Fazio R; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Zhu Y; Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Miceli R; Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Bouche O; Department of Digestive Oncology, CHU Reims, Reims, France., Modest DP; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany., Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Source: Journal of the National Cancer Institute [J Natl Cancer Inst] 2026 May 22. Date of Electronic Publication: 2026 May 22.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42178223
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Raimondi+A%22">Raimondi A</searchLink>; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Tinè+G%22">Tinè G</searchLink>; Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Boige+V%22">Boige V</searchLink>; Department of Oncologic Medicine, Gustave-Roussy, Villejuif Cedex, France.<br /><searchLink fieldCode="AU" term="%22Ballhausen+A%22">Ballhausen A</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Gourgou+S%22">Gourgou S</searchLink>; Biometrics Unit, Cancer Institute of Montpellier, Montpellier, France.<br /><searchLink fieldCode="AU" term="%22Stahler+A%22">Stahler A</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Randon+G%22">Randon G</searchLink>; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Manca+P%22">Manca P</searchLink>; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Brument+E%22">Brument E</searchLink>; UCGI, Prodige Intergroup, UNICANCER, Paris, France.<br /><searchLink fieldCode="AU" term="%22Alig+AHS%22">Alig AHS</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Morano+F%22">Morano F</searchLink>; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Prisciandaro+M%22">Prisciandaro M</searchLink>; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Ambrosini+M%22">Ambrosini M</searchLink>; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Fazio+R%22">Fazio R</searchLink>; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Zhu+Y%22">Zhu Y</searchLink>; Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Miceli+R%22">Miceli R</searchLink>; Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Bouche+O%22">Bouche O</searchLink>; Department of Digestive Oncology, CHU Reims, Reims, France.<br /><searchLink fieldCode="AU" term="%22Modest+DP%22">Modest DP</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Pietrantonio+F%22">Pietrantonio F</searchLink>; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227503089%22">Journal of the National Cancer Institute</searchLink> [J Natl Cancer Inst] 2026 May 22. <i>Date of Electronic Publication: </i>2026 May 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7503089 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1460-2105 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200278874%22">00278874 </searchLink><i>NLM ISO Abbreviation: </i>J Natl Cancer Inst <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42178223
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/jnci/djag160
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Raimondi A
      – PersonEntity:
          Name:
            NameFull: Tinè G
      – PersonEntity:
          Name:
            NameFull: Boige V
      – PersonEntity:
          Name:
            NameFull: Ballhausen A
      – PersonEntity:
          Name:
            NameFull: Gourgou S
      – PersonEntity:
          Name:
            NameFull: Stahler A
      – PersonEntity:
          Name:
            NameFull: Randon G
      – PersonEntity:
          Name:
            NameFull: Manca P
      – PersonEntity:
          Name:
            NameFull: Brument E
      – PersonEntity:
          Name:
            NameFull: Alig AHS
      – PersonEntity:
          Name:
            NameFull: Morano F
      – PersonEntity:
          Name:
            NameFull: Prisciandaro M
      – PersonEntity:
          Name:
            NameFull: Ambrosini M
      – PersonEntity:
          Name:
            NameFull: Fazio R
      – PersonEntity:
          Name:
            NameFull: Zhu Y
      – PersonEntity:
          Name:
            NameFull: Miceli R
      – PersonEntity:
          Name:
            NameFull: Bouche O
      – PersonEntity:
          Name:
            NameFull: Modest DP
      – PersonEntity:
          Name:
            NameFull: Pietrantonio F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 05
              Text: 2026 May 22
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1460-2105
          Titles:
            – TitleFull: Journal of the National Cancer Institute
              Type: main
ResultId 1